Federal prosecutors allege that expensive wound allografts were applied without adequate conservative care, placed on infected or nonresponsive wounds, and used for terminally ill patients whose wounds allegedly could not heal, although every accusation remains unproven.
WASHINGTON, DC, August 22, 2026 — A federal indictment against Florida nurse practitioner Leigh Tesar places medical necessity at the center of an alleged Medicare wound-care fraud operation, describing expensive skin substitutes that prosecutors say were ordered, applied, documented, and billed despite serious clinical disqualifications.
The court filing alleges that some allografts were used without confirming earlier conservative treatment, some were continued after wounds failed to respond, and others were placed over infected wounds or wounds that allegedly could not heal because patients were terminally ill.
Those accusations distinguish the government’s case from a simple disagreement about coding, because prosecutors contend that clinical records, treatment decisions, referral arrangements, product pricing, and reimbursement claims were coordinated to make questionable or nonexistent services appear eligible for federal payment.
According to the federal indictment filed in the Middle District of Florida, Tesar and others generated more than $118 million in wound-care claims over about eighteen months, while Medicare allegedly paid Tesar and her Primecare business more than $61 million.
Tesar has been charged with five counts of health care fraud, one conspiracy count, and two counts alleging the payment of health care kickbacks, while registered nurses Walter Presha Junior and Koby Evans face conspiracy and alleged kickback-receipt charges.
The defendants have not been convicted; an indictment represents accusations rather than evidence establishing guilt, and the government must prove every charged element beyond a reasonable doubt through admissible testimony, authenticated records, expert analysis, and other evidence tested in court.
The Court Filing’s Medical-Necessity Theory
Medicare Part B can cover qualifying bioengineered skin substitutes, including certain amniotic membrane allografts made from human placental tissue, when providers use them to assist wound closure or skin growth under documented circumstances satisfying applicable coverage requirements.
The products are not inherently fraudulent or clinically improper, and they can serve patients with difficult chronic wounds, but federal reimbursement depends upon whether a specific product and application were reasonable, necessary, accurately represented, properly documented, and untainted by prohibited payments.
The indictment outlines several alleged routes to medically unnecessary treatment, including failing to attempt prior conservative measures, disregarding improvement already occurring through ordinary care, applying grafts amid infection, continuing unsuccessful treatment, and selecting products exclusively to increase profit.
Each theory raises a different evidentiary question: a missing prerequisite can be evaluated through earlier charts, an infected wound may require clinical testimony, failed improvement depends on measurements over time, and profit-driven selection requires evidence showing purpose and knowledge.
That complexity will make individual patient files crucial, since aggregate billing figures can reveal scale or suspicious patterns but cannot independently establish whether every application was clinically unjustified, falsely represented, knowingly improper, or connected to the charged fraudulent intent.
Conservative Care Was an Alleged Coverage Gateway
The indictment explains that Florida’s Medicare contractor required certain diabetic foot ulcers and venous leg ulcers to complete at least four documented weeks of conservative treatment before a skin substitute could qualify for reimbursement under the coverage guidance summarized by prosecutors.
Those preliminary measures could include debridement, pressure relief, infection control, and wound drainage management, while pre-service records were expected to identify the interventions attempted and explain why the wound had not responded adequately before graft treatment began.
Prosecutors allege that Tesar applied allografts without attempting or confirming this earlier treatment and without determining whether particular wounds were healing through conservative measures, thereby presenting graft applications as necessary when less costly care allegedly remained effective or insufficiently tested.
Those questions are not minor technicalities, because criminal liability depends upon what Tesar knew and intended when claims were submitted, rather than upon a retrospective expert identifying an isolated documentation weakness or disagreeing with one practitioner’s judgment.
Repeated Applications and Product Switching Draw Scrutiny
The court filing says applicable guidance tied continuing wound-care coverage to documented improvement, accepted treatment standards, consideration of medical conditions affecting healing, and a treatment duration realistically correlated with each patient’s expected capacity for restoration.
For the specified ulcer categories, the indictment says repeat applications were not considered reasonable and necessary after a previous graft failed, while switching among products during a defined twelve-week treatment course was generally not expected under the contractor’s coverage framework.
Prosecutors allege that Tesar nevertheless continued applying allografts after wounds were plainly not responding, an assertion likely to turn upon serial measurements, photographs, progress notes, product orders, application dates, and testimony from patients or other caregivers.
A nonhealing wound does not automatically prove fraud, because chronic wounds can resist appropriate treatment despite competent care, but continued high-cost applications become harder to justify when records allegedly show no improvement and applicable guidance discourages repeating unsuccessful interventions.
The indictment also describes messages discussing a product priced at $2,000 per square centimeter rather than $1,591, followed by an alleged plan to switch patients, as compensation connected with the costlier product would increase substantially.
Infected Wounds and Underlying Conditions
The coverage rules summarized in the indictment excluded specified skin substitutes for patients whose underlying conditions or aggravating factors were inadequately controlled, with uncontrolled diabetes and active infections identified as examples that could make the treatment ineligible for Medicare reimbursement.
Prosecutors accuse Tesar of applying allografts to infected wounds, a serious allegation because infection control ordinarily influences whether advanced wound products can work effectively and whether placing costly material over a compromised site is medically appropriate.
The defense may dispute whether suspected infections were active, clinically significant, or already managed, while also questioning whether the government has accurately matched product applications, chart entries, billing dates, and changing patient conditions across a lengthy course of care.
Nevertheless, if prosecutors establish that active infections were known, inadequately managed, and deliberately concealed while expensive products kept being billed, those facts could strongly support the allegation that reimbursement rather than healing drove the disputed applications.
Terminal Illness and Wounds Allegedly Unable to Heal
The indictment does not claim broadly that terminally ill people can never receive legitimate wound care, and it does not say that patients themselves were incapable of being cured solely because an allograft was considered clinically unsuitable.
Instead, prosecutors specifically allege that Tesar applied allografts to wounds that would not heal because the patient was terminally ill, a narrower assertion connecting the person’s prognosis and restoration potential with the claimed futility of repeated graft treatment.
That accusation introduces difficult questions about goals of care, because palliative wound management may appropriately prioritize comfort, odor control, infection prevention, dignity, or reduced dressing burden even when complete closure is no longer a realistic medical objective.
Medicare reimbursement for a high-cost graft still requires applicable coverage conditions, however, and prosecutors will likely distinguish supportive palliative care from repeated products allegedly billed as restorative treatment despite records showing that wound closure was not reasonably achievable.
Medical Records Allegedly Recast the Clinical Picture
Prosecutors allege that Tesar and others falsified patient charts so allograft applications appeared medically reasonable, necessary, and compliant, including records asserting that treatments occurred when none were rendered and that Tesar personally delivered earlier conservative care.
Other entries allegedly moved the documented appearance of wounds to earlier dates or misstated patient conditions, changes that could create the impression that prerequisite treatment periods had passed and that coverage standards were satisfied before costly applications began.
These allegations connect medical necessity with intent, because an honest mistake in treatment decisions raises a different criminal question than deliberately rewriting dates, conditions, prior interventions, or services to manufacture eligibility for payment after coverage requirements were understood.
Defense lawyers may question who authored particular entries, whether templates or staff created inaccurate language, whether later corrections were legitimate, and whether prosecutors can prove that Tesar knew about every disputed statement associated with Primecare’s claims.
Claims for Applications Prosecutors Say Never Happened
The government separately alleges that Medicare received claims for purported allograft applications that were never rendered, a theory distinct from medically unnecessary treatment because it asserts that some billed procedures did not occur at all.
An unnecessary service may still have been performed and can generate expert disagreement, whereas a nonexistent application can be tested through product inventories, delivery records, patient recollections, schedules, photographs, nursing notes, discarded packaging, and discrepancies among contemporaneous documents.
The indictment’s first five counts identify representative claims involving five beneficiaries and billed amounts ranging from approximately $288,350 to more than $1.11 million, with resulting Medicare payments ranging from roughly $199,769 to about $854,311.
Combined, those five charged transactions represent approximately $3.96 million billed and $2.82 million paid, although listing them in an indictment does not prove their falsity or establish that every dollar within the broader billing total reflected criminal conduct.
Independent WUSF and Health News Florida reporting on the federal takedown described the Tesar matter as one of the initiative’s largest alleged schemes and summarized accusations involving infected wounds, unlikely healing, unnecessary grafts, referral payments, and disputed services.
Primecare’s Alleged Role in the Billing Stream
The indictment says she certified compliance with Medicare laws, program instructions, truthful billing obligations, and the federal Anti-Kickback Statute, representations prosecutors will likely use to show knowledge of conditions governing payment and prohibited referral arrangements.
From approximately May 2024 through November 2025, prosecutors say Tesar and others generated more than $118 million in claims for products and services allegedly unnecessary, ineligible, misrepresented, unperformed, or obtained through unlawful kickbacks.
Following a Medicare audit, Tesar allegedly removed her name as Primecare’s owner from Florida corporate records while secretly retaining ownership and managerial control, conduct prosecutors characterize as an effort to avoid scrutiny while the challenged claims continued.
Referral Payments Allegedly Reinforced Product Use
The medical-necessity allegations sit inside a broader claimed referral system involving Presha, Evans, and a Pennsylvania distributor identified as Company-I, which allegedly engaged the nurses through purported sales agreements that prosecutors describe as shams.
The government says the nurses located Medicare beneficiaries with wounds and referred them to Tesar in return for compensation tied to allograft business, creating an alleged financial pipeline from patient access through treatment, billing, distributor accounting, and payment.
One message described in the indictment allegedly calculated Presha’s share at twenty percent of invoices exceeding $4.06 million, while another communication allegedly emphasized that Evans already had several patients who could begin treatment quickly.
The product-pricing messages are relevant to medical necessity because prosecutors may argue that higher prices enlarged referral compensation and encouraged switching, thereby aligning the interests of patient sources, the treating practice, and the distributor around more expensive applications.
In July 2025, Tesar allegedly sent a Company-I owner information matching Primecare payments with specific products, patients, and purported representatives, enabling the distributor to calculate which referral source would receive compensation for particular transactions.
On August 15, 2025, Company-I allegedly transferred approximately $397,570 into an account associated with Presha and about $10,998 into an account associated with Evans, transactions forming the basis of separate payment and receipt counts.
Beneficiary Inducements and Informed Choice
Prosecutors also allege that Tesar and others encouraged Medicare beneficiaries to begin or continue costly treatment by misrepresenting expenses, unlawfully waiving copayments, providing free medical supplies, and giving valuable items, including jewelry and a leather recliner.
Those accusations matter because patient consent can be distorted when a trusted clinician recommends treatment while undisclosed referral compensation operates behind the recommendation, particularly if waived costs or personal gifts reduce the beneficiary’s reason to question necessity.
No gift, waiver, or referral automatically proves that treatment was unnecessary, yet prosecutors can combine those facts with clinical records, product choices, nonhealing wounds, pricing discussions, and claims data to argue that financial incentives shaped the entire care pathway.
Patients and families should not stop necessary wound treatment because of a criminal case involving another provider, but they can seek independent advice and ask about treatment goals, alternatives, expected improvement, costs, product names, and financial relationships.
Forfeiture and Alleged Personal Spending
Authorities identify approximately $11.8 million already seized from financial accounts connected with the matter, although pretrial seizure does not establish that the assets were criminal proceeds, and ownership or traceability can be contested through forfeiture litigation.
Prosecutors allege the proceeds funded more than $215,000 in Tampa Bay Buccaneers tickets and a luxury suite at Raymond James Stadium, along with more than $400,000 spent acquiring fine art for personal enjoyment.
Luxury purchases can make an indictment memorable, but they do not prove the medical falsity of any claim, meaning the government must still connect specific funds to charged conduct and establish the underlying offenses beyond a reasonable doubt.
Charges, Defenses, and the Burden of Proof
Counts One through Five charge Tesar with health care fraud involving individual claims, Count Six charges all three defendants with a conspiracy affecting Medicare and alleged kickbacks, and Counts Seven through Ten address two disputed payments from opposite sides.
To convict Tesar of health care fraud, prosecutors must establish a knowing and willful scheme involving materially false claims, while mere negligence, poor documentation, clinical disagreement, or an innocent billing mistake would not independently satisfy that burden.
Her defense may dispute medical necessity, coverage interpretations, authorship of records, responsibility for claims, reliance upon employees or suppliers, the purpose of product changes, and whether any questioned application reflected an intent to deceive rather than flawed judgment.
Presha and Evans may argue that their agreements covered genuine commercial services, that compensation was not paid for referrals, or that they lacked knowledge of allegedly false claims, while prosecutors will emphasize patient-specific communications and percentage calculations.
Conspiracy liability requires proof of knowing participation in a shared unlawful objective, so professional association, commercial payment, or awareness of patient referrals cannot automatically establish that any defendant agreed to defraud the government or violate kickback restrictions.
Expert Evidence Could Decide the Clinical Disputes
Wound-care specialists may review ulcer type, size, depth, duration, blood flow, infection, underlying disease, conservative measures, serial response, prognosis, and product selection to determine whether each challenged application aligned with reasonable clinical practice.
Reimbursement experts may explain Medicare Part B rules, contractor guidance, coding, provider certifications, documentation expectations, product acquisition, claim submission, payment calculations, and how a clinical decision becomes a federal reimbursement request processed through administrative systems.
Patient testimony could establish whether applications occurred, what explanations were provided, whether wounds improved, and whether gifts or waived costs influenced decisions, although memory, illness, time, and complex caregiving arrangements may affect reliability.
A Case Within the 2026 National Takedown
The Tesar indictment emerged from the Justice Department’s 2026 National Health Care Fraud Takedown, which announced charges against 455 defendants across fifty-six federal districts and alleged more than $6.5 billion in false claims involving numerous schemes.
Skin-substitute cases received particular attention because high per-square-centimeter reimbursement could generate enormous claims, creating incentives for manufacturers, distributors, marketers, referral sources, practitioners, and billing entities whenever expensive products covered larger wounds or were applied repeatedly.
The Tesar prosecution illustrates that federal scrutiny can move from statistical anomalies to bedside decisions, asking whether actual patients received suitable treatment, whether records accurately captured their conditions, and whether financial arrangements influenced clinical judgment.
Compliance Lessons for Wound-Care Providers
Providers can reduce comparable risk by documenting conservative treatment, infection status, wound measurements, improvement, underlying conditions, restoration potential, product rationale, treatment changes, and reasons for continuing or stopping expensive applications within each patient’s contemporaneous record.
Organizations should independently audit high-cost graft utilization, monitor product switching and failed improvement, compare purchased inventory with billed quantities, review unusual provider volumes, and require escalation when clinical records do not clearly support continuing treatment.
Referral and distributor contracts deserve separate scrutiny, including whether representatives perform legitimate, documented services; whether compensation reflects fair market value; whether payments vary with patient revenue; and whether clinicians know about financial interests affecting recommendations.
Compliance programs should also examine routine copayment waivers, valuable beneficiary gifts, pressure to locate wounds, instructions to conceal financial discussions, ownership changes after audits, and records modified to make previously ineligible care appear covered.
Public Allegations and Reputational Consequences
Major health care indictments quickly enter search engines, licensing discussions, payer reviews, employer decisions, banking compliance systems, and international screening databases, creating consequences long before a jury determines whether prosecutors can prove the allegations.
The Amicus International Consulting news and analysis hub follows health care fraud, asset seizure, extradition, identity, and cross-border enforcement matters while carefully distinguishing unresolved accusations from guilty pleas, verdicts, civil settlements, and final judicial findings.
Professionals and organizations facing intense scrutiny may also review Amicus International Consulting’s crisis communications and reputation-management guidance, which emphasizes disciplined factual review, coordinated stakeholder messaging, careful media preparation, and respect for active legal proceedings.
Responsible communication must never conceal records, pressure witnesses, mislead patients, obstruct investigators, or present unsupported claims as facts, but it can keep procedural context, accurate updates, and the presumption of innocence visible beside dramatic allegations.
What Happens Next
The case can proceed through discovery, expert review, evidentiary motions, challenges to searches or statements, forfeiture litigation, plea negotiations, or trial, with patient-level clinical evidence likely to determine whether the broad medical-necessity theory survives adversarial testing.
Prosecutors will attempt to connect wound conditions, inadequate conservative care, failed response, terminal prognosis, disputed records, high-cost product choices, referrals, payments, and claims into one deliberate scheme driven by federal reimbursement rather than patient benefit.
Defense counsel will try to separate those components, showing where legitimate treatment, evolving conditions, administrative error, independent commercial activity, incomplete documentation, or ambiguous communications may offer explanations inconsistent with knowing and willful fraud.
Until a plea, verdict, dismissal, or other judicial resolution establishes the outcome, the court filings remain unproven allegations that a Sarasota wound-care practice transformed vulnerable patients and sophisticated medical products into an extraordinarily profitable Medicare billing operation.
